UPDATE: Barclays Downgrades Ariad Pharmaceuticals Following News of Iclusig Clinical Hold
In a report published Thursday, Barclays analyst Ying Huang downgraded the rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Overweight to Underweight, and lowered the price target from $25.00 to $4.00.
In the report, Barclays noted, “We are downgrading ARIA to UW from OW and reducing our price target to $4 from $25, on higher risk of Iclusig not receiving FDA approval as a front-line therapy for chronic myeloid leukemia (CML) and reduced peak sales in second-line treatment given safety concerns around cardiovascular, cerebrovascular, and peripheral vascular thrombosis. We see risk/reward skewed to the downside at current levels.”
Ariad Pharmaceuticals closed on Wednesday at $5.83.
Latest Ratings for ARIA
|May 2016||Cowen & Company||Upgrades||Market Perform||Outperform|
|Mar 2016||JMP Securities||Maintains||Market Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.